DYNE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.73 USD | +4.37% |
|
+3.65% | +85.94% |
| Mar. 25 | Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell | MT |
| Mar. 25 | Dyne Therapeutics, Inc. Announces Management Changes | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 954.3 | 606 | 604.1 | 816.3 | 2,131 | - | - |
| Enterprise Value (EV) 1 | 609 | 229.5 | 348.1 | 693.2 | 1,575 | 1,792 | 2,131 |
| P/E ratio | -5.08 x | -4.06 x | -3.59 x | -3.37 x | -7.6 x | -7.8 x | -9.02 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 139 x | 37.9 x |
| EV / Revenue | - | - | - | - | - | 117 x | 37.9 x |
| EV / EBITDA | -10.5 x | -1.54 x | -2.06 x | -2.88 x | -7.03 x | -7.53 x | - |
| EV / FCF | -12.8 x | -1.86 x | -2.22 x | -3.67 x | -6.13 x | -7.78 x | -10.1 x |
| FCF Yield | -7.83% | -53.7% | -45% | -27.2% | -16.3% | -12.9% | -9.94% |
| Price to Book | 2.79 x | 1.67 x | 2.39 x | 8.7 x | 8.1 x | 6.02 x | - |
| Nbr of stocks (in thousands) | 45,445 | 50,970 | 52,124 | 61,376 | 86,175 | - | - |
| Reference price 2 | 21.00 | 11.89 | 11.59 | 13.30 | 24.73 | 24.73 | 24.73 |
| Announcement Date | 3/4/21 | 3/10/22 | 3/2/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 15.32 | 56.16 |
| EBITDA 1 | - | -57.95 | -148.9 | -169.3 | -240.5 | -224.1 | -238 | - |
| EBIT 1 | - | -58.65 | -150 | -171 | -242.2 | -281.6 | -293.8 | -288.7 |
| Operating Margin | - | - | - | - | - | - | -1,917.4% | -514.07% |
| Earnings before Tax (EBT) 1 | - | -59.44 | -149.3 | -168.1 | -235.9 | -272.9 | -306 | -339.1 |
| Net income 1 | -14.86 | -59.44 | -149.3 | -168.1 | -235.9 | -274.1 | -288.4 | -276.9 |
| Net margin | - | - | - | - | - | - | -1,881.91% | -493.07% |
| EPS 2 | -1.830 | -4.130 | -2.930 | -3.230 | -3.950 | -3.252 | -3.171 | -2.742 |
| Free Cash Flow 1 | - | -47.67 | -123.2 | -156.7 | -188.9 | -256.7 | -230.5 | -211.9 |
| FCF margin | - | - | - | - | - | - | -1,504.28% | -377.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/25/20 | 3/4/21 | 3/10/22 | 3/2/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -42.51 | -51.62 | -35.36 | -52.3 | -41.88 | -39.74 | -45.05 | -66.3 | -61.84 | -67.29 | - | - | - | - | - |
| EBIT 1 | -42.77 | -51.96 | -35.78 | -52.76 | -42.28 | -40.15 | -45.46 | -66.74 | -62.27 | -67.69 | -67.09 | -68.84 | -71.1 | -72.89 | -87 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -42.58 | -51.79 | -35.58 | -52.3 | -41.38 | -38.83 | -44.19 | -64.9 | -60.21 | -66.64 | -64.42 | -65.78 | -67.46 | -70.42 | -85 |
| Net income 1 | -42.58 | -51.79 | -35.58 | -52.3 | -41.38 | -38.83 | -44.19 | -64.9 | -60.21 | -66.64 | -65.34 | -66.36 | -68.64 | -70.73 | -85 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8300 | -1.000 | -0.6900 | -1.010 | -0.8000 | -0.7400 | -0.7800 | -1.080 | -0.9900 | -1.090 | -0.8043 | -0.8114 | -0.8329 | -0.8314 | -1.020 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/10/22 | 5/2/22 | 8/4/22 | 11/3/22 | 3/2/23 | 5/11/23 | 8/3/23 | 10/30/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 345 | 377 | 256 | 123 | 556 | 339 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -47.7 | -123 | -157 | -189 | -257 | -231 | -212 |
| ROE (net income / shareholders' equity) | - | -33.4% | -42% | -54.2% | -137% | -144% | -78.2% | - |
| ROA (Net income/ Total Assets) | - | -32.2% | -38.3% | -45.9% | -100% | -103% | -64.6% | - |
| Assets 1 | - | 184.9 | 389.5 | 366 | 235.7 | 266.9 | 446.4 | - |
| Book Value Per Share 2 | - | 7.530 | 7.140 | 4.860 | 1.530 | 3.050 | 4.110 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 1.16 | 3.62 | 3.07 | 0.73 | 2.11 | 2.18 | 2.74 |
| Capex / Sales | - | - | - | - | - | - | 14.24% | 4.88% |
| Announcement Date | 8/25/20 | 3/4/21 | 3/10/22 | 3/2/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.73
USD
Average target price
37.56
USD
Spread / Average Target
+51.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +85.94% | 2.13B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DYN Stock
- Financials Dyne Therapeutics, Inc.
